NuCana PLCNASDAQ:NCNANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4200
- TODAY'S CHANGE (%)0.0070 (1.6949%)
- Bid / Lots0.4000/ 9
- Ask / Lots0.4200/ 2
- Open / Previous Close0.4800 / 0.4130
- Day Range
- 52 Week Range
- Volume141,879
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NCNA |
|---|---|---|
| 09:32 ET | 9002 | 0.41 |
| 09:53 ET | 56700 | 0.41 |
| 09:57 ET | 1000 | 0.412 |
| 10:56 ET | 1194 | 0.42 |
| 10:58 ET | 400 | 0.42 |
| 11:43 ET | 100 | 0.42 |
| 11:45 ET | 100 | 0.4101 |
| 11:57 ET | 200 | 0.415 |
| 12:01 ET | 5000 | 0.4198 |
| 12:06 ET | 33727 | 0.3807 |
| 12:08 ET | 2373 | 0.3919 |
| 12:14 ET | 2000 | 0.4251 |
| 12:19 ET | 550 | 0.4201 |
| 12:24 ET | 1300 | 0.4202 |
| 12:26 ET | 2000 | 0.417 |
| 01:24 ET | 200 | 0.44 |
| 01:31 ET | 2200 | 0.43 |
| 01:49 ET | 3004 | 0.43 |
| 01:51 ET | 200 | 0.425 |
| 02:09 ET | 1900 | 0.4151 |
| 02:18 ET | 5896 | 0.4151 |
| 02:20 ET | 100 | 0.4151 |
| 02:21 ET | 3000 | 0.4104 |
| 02:41 ET | 100 | 0.44 |
| 02:54 ET | 500 | 0.425151 |
| 03:37 ET | 1000 | 0.4201 |
| 03:55 ET | 200 | 0.44 |
| 03:57 ET | 100 | 0.44 |
| 04:00 ET | 5479 | 0.42 |
Nov 21, 2023
DJ NuCana Price Target Maintained With a $4.00/Share by Oppenheimer, from 11:25AM ET on Tuesday Nov 21, 2023 by Dow Jones
11:25AM ET on Tuesday Nov 21, 2023 by Dow Jones
Nov 16, 2023
Press Release: NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update, from 4:01PM ET on Thursday Nov 16, 2023 by Dow Jones
4:01PM ET on Thursday Nov 16, 2023 by Dow JonesNuCana Reports Third Quarter 2023 Financial Results and Provides Business Update, from 4:01PM ET on Thursday Nov 16, 2023 by Dow Jones
4:01PM ET on Thursday Nov 16, 2023 by Dow Jones
Nov 10, 2023
NuCana Announces Listing Transfer to Nasdaq Capital Market, from 4:01PM ET on Friday Nov 10, 2023 by Dow Jones
4:01PM ET on Friday Nov 10, 2023 by Dow Jones
Nov 8, 2023
NuCana to Present at the Jefferies London Healthcare Conference, from 4:01PM ET on Wednesday Nov 08, 2023 by Dow Jones
4:01PM ET on Wednesday Nov 08, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NuCana PLC | 22.2M | -0.5x | --- |
Ocean Biomedical Inc | 28.1M | -0.3x | --- |
Regulus Therapeutics Inc | 28.3M | -0.9x | --- |
Iterum Therapeutics PLC | 27.7M | -0.9x | --- |
Eledon Pharmaceuticals Inc | 27.6M | -0.2x | --- |
Xilio Therapeutics Inc | 28.6M | -0.4x | --- |
Company Information
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Contact Information
- Headquarters
- Lochside House, 3 Lochside WayEDINBURGH, United Kingdom EH12 9DT
- Phone
- 131-248-3660
- Fax
- 131-248-3001
Executives
- Non-Executive Independent Chairman of the Board
- Andrew Kay
- Chief Executive Officer, Co-Founder, Executive Director
- Hugh Griffith
- Chief Financial Officer
- Donald Munoz
- Chief Medical Officer
- Jeffrey Bloss
- Head - Translational Studies
- David Harrison
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $-0.85 |
Book Value | $0.93 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
